 H.C. Wainwright raised the price target on Outlook Therapeutics Inc NASDAQ:OTLK to 6 from 5 and reiterated a Buy rating. The Company announced exceptionally strong data that showed Lytenavas statistically significant superiority over Lucentis, analyst Douglas Tsao tells investors in a research note. 